全文获取类型
收费全文 | 68713篇 |
免费 | 6841篇 |
国内免费 | 2292篇 |
专业分类
耳鼻咽喉 | 152篇 |
儿科学 | 815篇 |
妇产科学 | 452篇 |
基础医学 | 2669篇 |
口腔科学 | 452篇 |
临床医学 | 8395篇 |
内科学 | 7290篇 |
皮肤病学 | 1197篇 |
神经病学 | 2206篇 |
特种医学 | 857篇 |
外国民族医学 | 7篇 |
外科学 | 2496篇 |
综合类 | 9072篇 |
现状与发展 | 5篇 |
一般理论 | 3篇 |
预防医学 | 4886篇 |
眼科学 | 662篇 |
药学 | 29542篇 |
32篇 | |
中国医学 | 3015篇 |
肿瘤学 | 3641篇 |
出版年
2024年 | 70篇 |
2023年 | 1163篇 |
2022年 | 1479篇 |
2021年 | 2452篇 |
2020年 | 2655篇 |
2019年 | 2787篇 |
2018年 | 2802篇 |
2017年 | 2906篇 |
2016年 | 2605篇 |
2015年 | 2632篇 |
2014年 | 4714篇 |
2013年 | 7448篇 |
2012年 | 4691篇 |
2011年 | 4838篇 |
2010年 | 3917篇 |
2009年 | 3409篇 |
2008年 | 3172篇 |
2007年 | 3190篇 |
2006年 | 2862篇 |
2005年 | 2506篇 |
2004年 | 2137篇 |
2003年 | 1912篇 |
2002年 | 1448篇 |
2001年 | 1373篇 |
2000年 | 1054篇 |
1999年 | 901篇 |
1998年 | 764篇 |
1997年 | 707篇 |
1996年 | 590篇 |
1995年 | 559篇 |
1994年 | 480篇 |
1993年 | 401篇 |
1992年 | 458篇 |
1991年 | 385篇 |
1990年 | 307篇 |
1989年 | 246篇 |
1988年 | 247篇 |
1987年 | 240篇 |
1986年 | 184篇 |
1985年 | 216篇 |
1984年 | 190篇 |
1983年 | 137篇 |
1982年 | 117篇 |
1981年 | 92篇 |
1980年 | 61篇 |
1979年 | 59篇 |
1978年 | 69篇 |
1977年 | 48篇 |
1976年 | 49篇 |
1975年 | 51篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
目的:探讨电针联合右美托咪定对老年骨科患者术中应激的影响。方法:选取拟行手术治疗的老年下肢骨折患者56例为研究对象,采用随机数字表法分为单纯全麻组、电针复合全麻组(简称复合电针组)、右美托咪定复合全麻组(简称复合右美组)及电针联合右美托咪定复合全麻组(简称针药复合组),各14例。记录各组各时间点血压、心率、血氧饱和度等各项监护指标,术前、术后神经心理学指标(简易智力检查评分和疼痛视觉模拟评分)及各时间点血糖水平,术中心血管活性药物使用情况及患者住院天数。结果:术后各时间点针药复合组简易智力检查评分高于单纯全麻组(P<0.05);术后72 h内,针药复合组疼痛评分低于其他三组(P<0.05);针药复合组术中循环系统指标及血糖水平更稳定;针药复合组术后意识恢复时间最短(P<0.05);四组术后呼吸恢复时间与住院天数比较,差异无统计学意义(P>0.05);四组心血管活性药物使用率比较,差异无统计学意义(P>0.05)。结论:老年骨科患者手术中采用电针联合右美托咪定治疗,能够稳定围术期血糖、术中循环系统指标水平,减少术后认知功能障碍发生率,显著降低术中应激水平。 相似文献
102.
103.
《Vaccine》2021,39(40):5858-5865
BackgroundEnteric fever, caused by Salmonella Typhi and S. Paratyphi, is a cause of high morbidity and mortality among children in South Asia. Rising antimicrobial resistance presents an additional challenge. Typhoid Conjugate Vaccines (TCV) are recommended by the World Health Organization for use among people 6 months to 45 years old living in endemic settings. This study aimed to assess the effectiveness of TCV against culture-confirmed S. Typhi in Lyari Town, Karachi, Pakistan. This peri-urban town was one of the worst affected by the outbreak of extensively drug resistant (XDR) typhoid that started in November 2016.MethodsA matched case-control study was conducted following a mass immunization campaign with TCV at three key hospitals in Lyari Town Karachi, Pakistan. Children aged 6 months to 15 years presenting with culture-confirmed S. Typhi were enrolled as cases. For each case, at least 1 age-matched hospital control and two age-matched community controls were enrolled. Adjusted odds ratios with 95% confidence intervals (CIs) were calculated using conditional logistic regression.ResultsOf 82 typhoid fever patients enrolled from August 2019 through December 2019, 8 (9·8%) had received vaccine for typhoid. Of the 164 community controls and 82 hospital controls enrolled, 38 (23·2%) community controls and 27 (32·9%) hospital controls were vaccinated for typhoid. The age and sex-adjusted vaccine effectiveness was found to be 72% (95% CI: 34% − 88%). The consumption of meals prepared outside home more than once per month (adjusted odds ratio: 3·72, 95% CI: 1·55- 8·94; p-value: 0·003) was associated with the development of culture-confirmed typhoid.ConclusionA single dose of TCV is effective against culture confirmed typhoid among children aged 6 months to 15 years old in an XDR typhoid outbreak setting of a peri-urban community in Karachi, Pakistan. 相似文献
104.
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by drug resistance. This review covers the historical background of studies on the structure and function of HIV protease, the subsequent development of antiviral inhibitors, and recent studies on drug-resistant protease variants. We highlight the important contributions of Dr. Stephen Oroszlan to fundamental knowledge about the function of the HIV protease and other retroviral proteases. These studies, along with those of his colleagues, laid the foundations for the design of clinical inhibitors of HIV protease. The drug-resistant protease variants also provide an excellent model for investigating the molecular mechanisms and evolution of resistance. 相似文献
105.
106.
目的探讨细胞色素P450药物代谢酶(CYP)2C19基因分型与氯吡格雷治疗的急性缺血性脑卒中患者再发脑卒中的关系。方法选取2018年5月—2018年12月常州市第一人民医院收治接受氯吡格雷治疗的159例急性缺血性脑卒中患者,检测患者入院后空腹外周血中CYP2C19*2,CYP2C19*3基因分型。对患者进行随访,随访截至2020年2月,观察再发脑卒中的情况,并分析CYP2C19*2,CYP2C19*3基因分型与再发脑卒中关系。结果随访时间14~22个月,平均随访时间为(18.2±1.5)个月,共7例患者失访,共20例(13.2%)患者复发缺血性脑卒中。再发脑卒中患者中CYP2C19*2 GG型及CYP2C19*3 GG型均低于无复发患者(P<0.05),CYP2C19*2 GA型,CYP2C19*2 AA型CYP2C19*3 GA型,CYP2C19*3AA型均高于无复发患者(P<0.05)。Kaplan-Meier法并Log-rank检验结果显示,CYP2C19*2 GG型无复发时间长于AA型,差异有统计学意义(Log-rank=6.759,P=0.034)。CYP2C19*3GG型无复发时间长于AA型,差异有统计学意义(Log-rank x2=8.660,P=0.013)。多因素Cox分析结果显示,糖尿病、氯吡格雷抵抗,CYP2C19*2及CYP2C19*3基因型是再发脑卒中影响因素(P<0.05)。结论在接受氯吡格雷治疗急性缺血性脑卒中患者中,CYP2C19*2及CYP2C19*3突变型再发脑卒中的风险明显增高。 相似文献
107.
Epilepsy is one of the most common chronic disorders affecting women of childbearing age. Unfortunately, many women with epilepsy (WWE) still report not receiving key information about pregnancy. They obviously need information about epilepsy and pregnancy prior to conception with a particular emphasis on effective birth control (i.e. contraception), necessity to plan pregnancy, antiepileptic drugs optimization, and folate supplementation. The risks associated with use of antiepileptic drugs during pregnancy have to be balanced against fetal and maternal risks associated with uncontrolled seizures. This report reviews evidence-based counseling and management strategies concerning maternal and fetal risks associated with seizures, teratogenic risks associated with antiepileptic drug exposure with a special emphasis on developmental and behavioural outcomes of children exposed to intra utero antiepileptic drugs. 相似文献
108.
109.
110.
肺动脉高压为恶性肺血管疾病或临床综合征,发病机理涉及复杂的生物学过程和多种分子机制,临床仍缺乏有效治疗药物。尽管单靶点药物的联合应用可有效改善其临床症状,但不能阻止病程进展,且价格昂贵,药物不良反应问题一直未能解决。中药因多成分协同作用、多靶点发挥药效、多途径整合调节疾病的特点,在肺动脉高压的治疗中发挥独特优势,具有良好应用前景和创新药物开发潜力。本文旨在全面系统地梳理近30年中药防治肺动脉高压的研究进展,分析创新药物研发的瓶颈及策略,以期为肺动脉高压的创新药物研发提供有益参考。 相似文献